Sales increased 2% year over year to $5 billion, falling short of the $5.1 billion analyst consensus. Teva's earnings increased 8% to $1.22 per share and American Depositary Receipt, matching Wall Street's expectations.
The generics segment reported 3% year-over-year sales growth, accounting for 46% of Teva's total revenue. The segment was helped by the release of new medications in Europe and North America, but hindered by a mild European winter and increased competition in America.
In the specialty segment, sales increased by 3%. The gain was driven by more than 20% growth in Parkinson's disease treatment Azilect, narcolepsy medication Nuvigil, and asthma inhalator drug ProAir.
The over-the-counter division saw sales of $269 million, a 12% decrease from the year-ago period. This drop was driven by "an exceptionally weak cough and cold season in Europe and Russia," according to Teva.
The Israel-based company launched a modified version of its blockbuster Copaxone multiple sclerosis medication during the quarter. About one-third of all Copaxone patients in America have already switched to the new thrice-a-week dosing schedule.
"We are intensely focused on solidifying the foundation of Teva, maintaining the Copaxone franchise, driving sustainable organic growth, and positioning Teva for long-term value creation," said CEO Erez Vigodman in a prepared statement.
More from The Motley Fool
The Laundry List of Reasons Behind Teva Pharmaceutical Industries' 48% Tumble in 2017
Teva threw everything but the kitchen sink at its shareholders last year, but the future is beginning to look brighter.
The Big Reason Teva Pharmaceutical Industries Catapulted 28% Higher in December
Plans to "trim the fat" have Wall Street and investors excited.
Billionaire George Soros Is Betting Big Against These 2 Pharma Stocks
Can Valeant and Teva rebound? George Soros' namesake fund doesn't seem to think so.